{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:10:08Z","timestamp":1793387408413,"version":"4.5.0"},"reference-count":74,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The interleukin\u201023 (IL\u201023) inhibitor risankizumab was recently approved for the treatment of moderate\u2010to\u2010severe plaque psoriasis in the United States. Low rates of cerebrovascular accident (CVA) were observed in risankizumab\u2010treated patients during clinical trials. The aim of this study was to determine whether risankizumab may be associated with CVA in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective disproportionality analysis was conducted utilizing postmarketing adverse event reports submitted to the US Food and Drug Administration Adverse Event Reporting System (FAERS) through the fourth quarter of 2021. A custom query consisting of 22 CVA\u2010related Medical Dictionary for Regulatory Activities (MedDRA) preferred terms previously reported in clinical trials of plaque psoriasis medications was used to identify cases. Disproportionality was measured by calculating reporting odds ratios (ROR) and 95% confidence intervals (CI), whereby the lower limit of a 95% CI &gt;1.0 and \u2265 three cases was considered a signal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Risankizumab was associated with significantly disproportionate CVA reporting compared to all other drugs in FAERS (ROR 2.48; 95% CI 2.14\u20132.88) as well as 11 alternative plaque psoriasis therapeutics across five pharmacologic classes. The largest disproportionality signals for risankizumab were identified relative to apremilast (ROR 9.07; 95% CI 7.56\u201310.89), ixekizumab (ROR 6.75; 95% CI 5.14\u20138.86), guselkumab (ROR 6.74; 95% CI 4.68\u20139.71), certolizumab (ROR 5.70; 95% CI 4.74\u20136.85) and etanercept (ROR 4.91; 95% CI 4.21\u20135.73).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study detected a previously unreported signal of disproportionate CVA reporting with the real\u2010world use of risankizumab. Further long\u2010term observational data will be necessary to better characterize this unconfirmed potential safety signal.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15581","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T13:14:22Z","timestamp":1667394862000},"page":"2386-2395","source":"Crossref","is-referenced-by-count":45,"title":["Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-9105","authenticated-orcid":false,"given":"Richard H.","family":"Woods","sequence":"first","affiliation":[{"name":"Levin, Papantonio, Rafferty, Proctor, Buchanan, O'Brien, Barr &amp; Mougey, P.A  Pensacola Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_9_4_1","unstructured":"Skyrizi\u00ae (risankizumab) [package insert]. North Chicago IL: AbbVie Inc;2022."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000950"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.149"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14964"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062382"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2012.04705.x"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010013\u20100018\u2010x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1614561"},{"key":"e_1_2_9_16_1","unstructured":"FDA.FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food and Drug Administration. Silver Spring MD.fis.fda.gov\/sense\/app\/95239e26\u2010e0be\u201042d9\u2010a960\u20109a5f7f1c25ee\/sheet\/33a0f68e\u2010845c\u201048e2\u2010bc81\u20108141c6aaf772\/state\/analysisAccessed February 21 2022."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.5772\/50095"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14751"},{"key":"e_1_2_9_20_1","unstructured":"FDA.NDA\/BLA Multi\u2010disciplinary Review and Evaluation \u2013 BLA 761105 (Skyrizi Risankizumab).2019. Beltsville MD: U.S. Food and Drug Administration.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761105Orig1s000MultidisciplineR.pdf. Accessed February 21 2022."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010017\u20100794\u20101"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000490\u20103"},{"key":"e_1_2_9_23_1","unstructured":"U.S. National Library of Medicine. NCT02672852. BI 655066\/ABBV\u2010066 (Risankizumab) in moderate to severe plaque psoriasis with randomized withdrawal and re\u2010treatment.clinicaltrials.gov\/ct2\/show\/NCT02672852. Accessed February 21 2022."},{"key":"e_1_2_9_24_1","unstructured":"U.S. National Library of Medicine. NCT02684357. BI 655066 versus placebo & active comparator (Ustekinumab) in patients with moderate to severe chronic plaque psoriasis.clinicaltrials.gov\/ct2\/show\/NCT02684357. Accessed February 21 2022."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1782817"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.026"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.07.026"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19314"},{"key":"e_1_2_9_33_1","unstructured":"U.S. National Library of Medicine.NCT00779675. Assessment of long\u2010term infliximab for psoriasis (P05319) (REALITY).clinicaltrials.gov\/ct2\/show\/NCT00779675. Accessed February 21 2022."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(08)60725\u20104"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.304"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1211"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2012.04500.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/247553031600100307"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.042"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.0001"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.2977"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7712587"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.043"},{"key":"e_1_2_9_45_1","unstructured":"U.S. National Library of Medicine.NCT04799990. Study to assess adverse events when subcutaneous risankizumab injection is given to adult participants with psoriasis in real world setting.clinicaltrials.gov\/ct2\/show\/NCT04799990. Accessed February 22 2022."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S167149"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010021\u201000612\u20109"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010014\u20101658\u20101"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2018.02.014"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.79986"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510703"},{"key":"e_1_2_9_53_1","unstructured":"FDA.Janus Kinase (JAK) inhibitors: drug safety communication: FDA requires warnings about increased risk of serious heart\u2010related events cancer blood clots and death.2021. Beltsville MD: U.S. Food and Drug Administration.fda.gov\/safety\/medical\u2010product\u2010safety\u2010information\/janus\u2010kinase\u2010jak\u2010inhibitors\u2010drug\u2010safety\u2010communication\u2010fda\u2010requires\u2010warnings\u2010about\u2010increased\u2010riskAccessed February 21 2022."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2011.12.010"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.114.006516"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0006"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033\u2010021\u201006339\u20104"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvab359"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.008257"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2019.0050"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.01.012"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2015.01.041"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090545"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.229997"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006133"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs263"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3979"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010016\u20100405\u20101"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010015\u20100388\u20103"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.18.1938"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1323867"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010017\u20100603\u20103"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010013\u20100063\u20105"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15581","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15581","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T03:52:29Z","timestamp":1734666749000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/bcp.15581"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15581","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]}}}